Transcatheter aortic valve implantation in low-risk patients: is it too early?

The median age of patients treated by transcatheter aortic valve implantation (TAVI) is falling across Europe, and low-risk patients with severe aortic stenosis (AS) represent 80% of patients with severe AS undergoing surgical aortic valve replacement (SAVR). There are few data for TAVI in low-risk...

Full description

Saved in:
Bibliographic Details
Published inHeart (British Cardiac Society) Vol. 105; no. Suppl 2; pp. s51 - s56
Main Author Sousa Uva, Miguel
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group LTD 01.03.2019
Subjects
Age
Heart
Hospitals
Kidneys
Mortality
Patients
Stroke
Surgeons
aortic surgery
Online AccessGet full text

Cover

More Information
Summary:The median age of patients treated by transcatheter aortic valve implantation (TAVI) is falling across Europe, and low-risk patients with severe aortic stenosis (AS) represent 80% of patients with severe AS undergoing surgical aortic valve replacement (SAVR). There are few data for TAVI in low-risk patients, but there are four ongoing randomised trials of SAVR versus TAVI. The key issues relate to pacemaker implantation rates and the associated potential longer term deleterious effects, and the need to minimise vascular complications and paravalvular leak. Valve leaflet thrombosis and paucity of data on valve durability remain a concern. Given the higher incidence of bicuspid aortic valves in younger patients, outcomes of TAVI in this setting need clarification and are discussed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1355-6037
1468-201X
DOI:10.1136/heartjnl-2018-314248